Jpmorgan Chase & CO Corcept Therapeutics Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 259,902 shares of CORT stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
259,902
Previous 253,070
2.7%
Holding current value
$16.5 Million
Previous $11.7 Million
11.86%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding CORT
# of Institutions
403Shares Held
84.3MCall Options Held
1.04MPut Options Held
1.33M-
Black Rock Inc. New York, NY16.5MShares$1.05 Billion0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$643 Million0.01% of portfolio
-
Ingalls & Snyder LLC New York, NY8.1MShares$515 Million16.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.2MShares$394 Million0.49% of portfolio
-
Parallel Advisors, LLC3.83MShares$243 Million4.44% of portfolio
About CORCEPT THERAPEUTICS INC
- Ticker CORT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,105,000
- Market Cap $6.81B
- Description
- Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...